Real-world study on the effectiveness of nirmatrelvir-ritonavir in reducing severe outcomes from COVID-19

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2023-184/ 2026 0980 010

Research Question/Objectives: Although the World Health Organization (WHO) has declared the end of COVID-19 as a global health emergency, signaling the end of the pandemic phase, COVID-19 patients will continue to require treatments and healthcare services, particularly for moderate to severe COVID-19 infections. These healthcare resources involve hospitalizations, intensive care unit (ICU) admission, mechanical ventilation use, and visits to the emergency department (ED), which incur direct costs to the healthcare system. Antiviral therapies for COVID-19 can prevent moderate to severe outcomes and reduce direct healthcare costs.

Objectives:

To understand the real-world effectiveness of nirmatrelvir-ritonavir in reducing severe outcomes from COVID-19 Ontario, this study will be conducted with the following objectives:

Primary Objective:

1. Assess the effect of nirmatrelvir-ritonavir treatment on time to the first severe composite outcome (all-cause hospital admission, ICU admission, or death) within 30 days of treatment assessment

Secondary Objective:

1. Assess the effect of nirmatrelvir-ritonavir treatment on time to first severe composite outcome (all-cause hospital admission, ICU admission, or death) within 60 days of treatment assessment

Exploratory Objective:

1. Assess the effect of nirmatrelvir-ritonavir on presence of a severe composite outcomes (all-cause and COVID-19-related hospital admission, all-cause and COVID-19-related ICU admission, or death) within 30 days or 60 days of treatment assessment

Status: In progress